overall survival

A bit of strategic cannibalism boosts overall survival chances for the larvae left "standing" when the music stops.

Overall survival and progression-free survival also did not differ in the two groups, the researchers note.

The primary endpoint was overall survival in all randomised patients who received study medication at least once.

In multivariate analysis, increasing age was an independent prognosticator of poor overall survival (P = . 041).

The overall survival ranges from less than one year to 10 years from the discovery of the metastasis and is similar in both tumor subtypes.

Median survival reflects one time point along the survival curve and does not measure the overall survival benefit.

Nodal status correlates with disease-free and overall survival better than other prognostic factors.

Neither progression-free survival nor overall survival differed significantly between the treatment arms.

We investigated whether letrozole monotherapy prolonged overall survival (OS) compared with tamoxifen monotherapy.

Overall survival and safety are among the secondary endpoints that will be assessed in the trial.

For patients with pathologic complete response, neoadjuvant therapy may give additional benefit in prolonging overall survival.

The addition of erlotinib to gemcitabine shows a small but significant improvement in overall survival (OS) versus gemcitabine alone.

Patients with advanced gastric cancer could benefit from chemotherapy with improvement in overall survival and quality of life.

Conclusions The IGS is strongly associated with metastasis-free survival and overall survival for four different types of tumors.

The study was designed to measure the length of time from when this treatment started until a patient's death (overall survival).

Primary and secondary endpoints were recurrence-free survival (RFS) and overall survival (OS), respectively.

To evaluate time distribution of brain metastases in patients with lung cancer, and influence of brain metastases on overall survival.

This study demonstrates the clinical value of circulating tumor cells in predicting progression-free and overall survival rates.

Secondary endpoints were overall response (intent to treat analysis) and overall survival.

The overall survival of patients with malignant ureteral obstruction remains poor.

secondary end points included overall survival, response rate, and toxic effects.

The outcome parameters assessed were overall survival and tumor-related survival.

A clinical benefit, such as improvement in progression-free survival or overall survival, has not been demonstrated.

The primary end point was amended from overall survival (OS) to progression-free survival (PFS).

The estimated overall survival rate for patients receiving Gleevec was 88% when considering deaths from all causes.

Primary efficacy endpoints were overall survival and time to symptomatic progression.

Overall survival (OS) and quality of life were secondary endpoints.

A limited number of genes were related to overall survival and cancer-free survival after LT.

The primary endpoint was overall survival, and analysis was per protocol.

In the last 30 years, we haven't done a lot to improve the overall survival of ovarian cancer patients.

The investigators are still assessing the overall survival data and will release their analysis later in 2004.

A trend toward better overall survival also was observed in the vaccine group, although the study was not powered to detect a difference.

The primary outcome measure was overall survival.

The differences of incidence of locoregional recurrence, disease free survival and overall survival at 5 years were compared.

The overall survival curves of the 2 cohorts were superimposable, the researchers commented.

All 185 patients were included in the analysis of progression-free and overall survival.

Results The overall survival rate was 93%, the ratio of recovery with favorable function was 85%.

For the 14 patients with ovarian cancer, the median time to progression was two months and the median overall survival was 15 months.

But median overall survival, a secondary end point, was 20. 5 months in the combination group and 20. 6 months in the monotherapy group.

At that time, the results for overall survival were not statistically significant, but now, with longer follow-up, they are.

The hazard ratio for overall survival was 0. 61 for the bortezomib group (P=0. 008).

Median overall survival was 46 weeks in the sorafenib group and 34 weeks in the placebo group (HR 0. 69, P =. 00058).

Overall survival and disease-free survival of radiofrequency ablation of hepatocellular carcinoma